阳普医疗(300030) - 2024 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2024 was ¥141,154,613.58, a decrease of 10.98% compared to ¥158,563,957.54 in the same period last year[5] - The net profit attributable to shareholders was -¥3,190,876.00, representing a decline of 123.40% from ¥13,633,861.49 in the previous year[5] - The company's total comprehensive income for the period was -¥2,873,883.12, a decrease of 120.28% from ¥14,171,251.31 in the previous year[10] - Net profit for Q1 2024 was a loss of ¥2,887,667.65, compared to a profit of ¥14,169,846.02 in Q1 2023, indicating a significant decline[34] - Basic earnings per share for Q1 2024 was -¥0.01, compared to ¥0.04 in the same quarter last year[35] Cash Flow - The net cash flow from operating activities improved to ¥16,000,253.94, a significant increase of 188.98% compared to -¥17,982,500.06 in the same period last year[5] - Operating cash flow decreased by 35.67% to CNY 130,888,648.85 from CNY 203,456,313.74 in the previous period[11] - Cash received from operating activities increased by 188.98% to CNY 16,000,253.94 compared to a negative CNY 17,982,500.06 in the previous period[11] - The net cash flow from investment activities was 2,869,383.28, a decrease from 15,812,418.98 in the previous year[37] - The net cash flow from financing activities was 6,651,198.39, down from 28,881,444.39 year-over-year[37] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,426,339,410.15, a slight increase of 0.03% from ¥1,425,956,329.46 at the end of the previous year[5] - The total liabilities increased slightly to ¥666,882,772.29 from ¥663,625,808.48, showing a marginal rise[34] - The total equity attributable to shareholders decreased to ¥719,907,384.16 from ¥723,084,475.63, reflecting a decline of about 0.6%[34] Investment and Expenses - The company reported an investment loss of -¥8,949,461.99, a decrease of 185.00% from an investment gain of ¥10,528,707.60 in the previous year[9] - Research and development expenses were ¥6,602,970.33, down from ¥9,259,547.98, representing a decrease of approximately 29%[33] - Cash inflow from investment activities decreased by 44.81% to CNY 49,218,402.82 from CNY 89,173,330.11 in the previous period[12] Shareholder Information - Total number of common shareholders at the end of the reporting period was 28,128[14] - The largest shareholder, Deng Guanhua, holds 15.91% of shares, totaling 49,194,555 shares[14] - The second largest shareholder, Zhuhai Gree Financial Investment Management Co., Ltd., holds 10.84% of shares, totaling 33,528,364 shares[14] Company Strategy and Operations - The company is focusing on expanding its market presence through technology and management innovation, aiming for synergistic development in domestic and international markets[19] - The company initiated a comprehensive training program for mid-level and senior management to enhance leadership and strategic skills, ensuring effective execution of company strategies[24] - The company is actively pursuing new product development in smart healthcare solutions, showcasing multiple new products at industry conferences[21] Miscellaneous - The chairman and general manager of the company is under investigation, with a temporary replacement appointed to fulfill his duties[27] - The company did not undergo an audit for the first quarter report[38] - The report is the first to apply new accounting standards starting from 2024[38]